Arrowhead Pharmaceuticals Inc
ARWR38.000USD
+0.650+1.74%
Close 10/24, 16:00（ET）Quotes delayed by 15 min
5.25BMarket Cap
LossP/E TTM
More Details of Arrowhead Pharmaceuticals Inc Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Arrowhead Pharmaceuticals Inc Info
Ticker SymbolARWR
Company nameArrowhead Pharmaceuticals Inc
IPO dateDec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
Number of employees609
Security typeOrdinary Share
Fiscal year-endDec 14
Address177 E Colorado Blvd
CityPASADENA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91105
Phone16266964702
Websitehttps://arrowheadpharma.com/
Ticker SymbolARWR
IPO dateDec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
Company Executives of Arrowhead Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
37.94K
+0.01%
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
35.78K
-2.60%
Mr. Daniel Apel
Mr. Daniel Apel
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Investment Management (US)
4.61%
Slate Path Capital LP
3.78%
Other
60.00%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Investment Management (US)
4.61%
Slate Path Capital LP
3.78%
Other
60.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.39%
Investment Advisor/Hedge Fund
23.32%
Hedge Fund
7.19%
Individual Investor
4.41%
Research Firm
2.62%
Sovereign Wealth Fund
1.41%
Pension Fund
0.96%
Bank and Trust
0.96%
Venture Capital
0.18%
Other
17.56%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
571
107.84M
78.00%
-10.82M
2025Q2
583
126.42M
91.54%
+6.47M
2025Q1
603
125.23M
90.71%
+6.54M
2024Q4
609
108.09M
85.81%
-8.58M
2024Q3
605
106.83M
85.95%
-7.44M
2024Q2
608
107.20M
86.35%
-5.57M
2024Q1
621
105.82M
85.63%
+13.72M
2023Q4
625
87.51M
81.46%
-1.31M
2023Q3
624
83.79M
78.09%
-822.40K
2023Q2
641
80.82M
75.59%
-4.71M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
17.60M
12.73%
-587.41K
-3.23%
Jun 30, 2025
The Vanguard Group, Inc.
15.50M
11.21%
+2.32M
+17.63%
Jun 30, 2025
Avoro Capital Advisors LLC
10.60M
7.67%
-511.11K
-4.60%
Jun 30, 2025
State Street Investment Management (US)
6.37M
4.61%
-628.19K
-8.98%
Jun 30, 2025
Slate Path Capital LP
5.23M
3.78%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.17M
3.74%
+1.86M
+55.96%
Jun 30, 2025
Anzalone (Christopher Richard)
3.92M
2.84%
-141.12K
-3.47%
Apr 11, 2025
Geode Capital Management, L.L.C.
2.98M
2.15%
+28.19K
+0.96%
Jun 30, 2025
Invus Public Equities Advisors, LLC
2.67M
1.93%
--
--
Jun 30, 2025
Marshall Wace LLP
2.16M
1.56%
+2.10M
+3507.76%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
Invesco Biotechnology & Genome ETF
3.69%
Global X Genomics & Biotechnology ETF
3%
ROBO Global Healthcare Technology & Innovation ETF
2.13%
Invesco S&P SmallCap Health Care ETF
1.87%
ALPS Medical Breakthroughs ETF
1.78%
Tema Heart & Health ETF
1.48%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
SPDR S&P Biotech ETF
0.76%
WisdomTree BioRevolution Fund
0.6%
Invesco NASDAQ Future Gen 200 ETF
0.54%
View more
Invesco Biotechnology & Genome ETF
Proportion3.69%
Global X Genomics & Biotechnology ETF
Proportion3%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.13%
Invesco S&P SmallCap Health Care ETF
Proportion1.87%
ALPS Medical Breakthroughs ETF
Proportion1.78%
Tema Heart & Health ETF
Proportion1.48%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.06%
SPDR S&P Biotech ETF
Proportion0.76%
WisdomTree BioRevolution Fund
Proportion0.6%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.54%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
